Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ertugliflozin

FDA-approved product (tablet, oral), marketed as Ertugliflozin, Steglatro.

Registered studies
49
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ertugliflozin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Ertugliflozin. Its therapeutic class is shown instead.

WHO therapeutic group
Sodium-glucose co-transporter 2 (sglt2) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae17.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ertugliflozin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ertugliflozin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study

    NCT04600921 · start 2021-06-24

    Registered record
    Registry ID
    NCT04600921
    Conditions
    Heart Failure With Reduced Ejection Fraction; Heart Failure With Mid Range Ejection Fraction; Implantable Cardioverter-Defibrillators; Cardiac Resynchronization Therapy
    Interventions
    Ertugliflozin 5 mg; Placebo 5mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-06-24
    Completion
    2023-10-18
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure With Reduced Ejection Fraction; Heart Failure With Mid Range Ejection Fraction; Implantable Cardioverter-Defibrillators; Cardiac Resynchronization Therapy
    InterventionErtugliflozin 5 mg; Placebo 5mg
    PhasePhase 3
    Registry statusTerminated

  • Ertugliflozin in Chronic Heart Failure

    NCT04438213 · start 2021-03-10

    Registered record
    Registry ID
    NCT04438213
    Conditions
    Heart Failure
    Interventions
    Ertugliflozin; Metolazone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2021-03-10
    Completion
    2025-12-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionErtugliflozin; Metolazone; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.

    NCT04027530 · start 2020-12-10

    Registered record
    Registry ID
    NCT04027530
    Conditions
    Type 2 Diabetes Mellitus; Diabetic Kidney Disease; Diabetic Nephropathy; Renal Hypoxia; Renoprotection; SGLT2 Inhibitor; Ertugliflozin
    Interventions
    Ertugliflozin 15 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-12-10
    Completion
    2023-01-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus; Diabetic Kidney Disease; Diabetic Nephropathy; Renal Hypoxia +3 more
    InterventionErtugliflozin 15 mg
    PhasePhase 4
    Registry statusCompleted

  • Ertugliflozin for Functional Mitral Regurgitation

    NCT04231331 · start 2020-11-04

    Registered record
    Registry ID
    NCT04231331
    Conditions
    Mitral Valve Insufficiency; Left Ventricular Systolic Dysfunction
    Interventions
    Ertugliflozin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-11-04
    Completion
    2023-11-15
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMitral Valve Insufficiency; Left Ventricular Systolic Dysfunction
    InterventionErtugliflozin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

    NCT04505774 · start 2020-09-04

    Registered record
    Registry ID
    NCT04505774
    Conditions
    Covid19
    Interventions
    theraputic heparin; prophylactic heparin; P2Y12; Crizanlizumab Injection; SGLT2 inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-09-04
    Completion
    2024-01-26
    Enrolment
    3,591

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    Interventiontheraputic heparin; prophylactic heparin; P2Y12; Crizanlizumab Injection +1 more
    PhasePhase 4
    Registry statusCompleted

  • SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study

    NCT05770687 · start 2020-08-01

    Registered record
    Registry ID
    NCT05770687
    Conditions
    Myocardial Infarction; Diabetes Mellitus, Type 2
    Interventions
    SGLT2 inhibitor
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2020-08-01
    Completion
    2026-12-31
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction; Diabetes Mellitus, Type 2
    InterventionSGLT2 inhibitor
    PhaseNot recorded
    Registry statusRecruiting

  • Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL)

    NCT04490681 · start 2020-08

    Registered record
    Registry ID
    NCT04490681
    Conditions
    Heart Failure With Nonischemic Cardiomyopathy
    Interventions
    Ertugliflozin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2020-08
    Completion
    2022-12
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure With Nonischemic Cardiomyopathy
    InterventionErtugliflozin; Placebo
    PhasePhase 3
    Registry statusUnknown

  • Ertugliflozin: Cardioprotective Effects on Epicardial Fat

    NCT04167761 · start 2020-07-01

    Registered record
    Registry ID
    NCT04167761
    Conditions
    Cardiovascular Diseases; Atherosclerosis; Type 2 Diabetes; Insulin Resistance
    Interventions
    Ertugliflozin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2020-07-01
    Completion
    2023-12-31
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Atherosclerosis; Type 2 Diabetes; Insulin Resistance
    InterventionErtugliflozin
    PhaseEarly phase 1
    Registry statusCompleted

  • Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure

    NCT04071626 · start 2020-03-01

    Registered record
    Registry ID
    NCT04071626
    Conditions
    Heart Failure, Diastolic; Diabetes Mellitus, Type 2
    Interventions
    Ertugliflozin 5 mg; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2020-03-01
    Completion
    2023-01-11
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure, Diastolic; Diabetes Mellitus, Type 2
    InterventionErtugliflozin 5 mg; Placebo oral tablet
    PhasePhase 4
    Registry statusTerminated

  • Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

    NCT04029480 · start 2019-10-08

    Registered record
    Registry ID
    NCT04029480
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Ertugliflozin 5 mg; Ertugliflozin 15 mg; Placebo to ertugliflozin 15 mg; Placebo to ertugliflozin 5 mg; Insulin; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-10-08
    Completion
    2025-04-11
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionErtugliflozin 5 mg; Ertugliflozin 15 mg; Placebo to ertugliflozin 15 mg; Placebo to ertugliflozin 5 mg +2 more
    PhasePhase 3
    Registry statusCompleted

  • Effect of Ertugliflozin on Cardiac Function in Diabetes

    NCT03717194 · start 2019-06-01

    Registered record
    Registry ID
    NCT03717194
    Conditions
    Type2 Diabetes; Heart Failure
    Interventions
    Ertugliflozin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-06-01
    Completion
    2023-04-30
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType2 Diabetes; Heart Failure
    InterventionErtugliflozin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Approaches To Therapy Escalation In T2D

    NCT03813316 · start 2019-05-01

    Registered record
    Registry ID
    NCT03813316
    Conditions
    Type2 Diabetes
    Interventions
    DPP-4 inhibitor; SGLT2 inhibitor; SGLT2 inhibitor and DPP-4 inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2019-05-01
    Completion
    2019-09-18
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType2 Diabetes
    InterventionDPP-4 inhibitor; SGLT2 inhibitor; SGLT2 inhibitor and DPP-4 inhibitor
    PhasePhase 4
    Registry statusWithdrawn

  • Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

    NCT03640221 · start 2018-09-01

    Registered record
    Registry ID
    NCT03640221
    Conditions
    Hypertension; Diabetes Mellitus, Type 2
    Interventions
    Ertugliflozin; Hydrochlorothiazide 12.5mg; Microneurography; SKNA recordings; Static Handgrip; Post-handgrip forearm vascular occlusion; Testing of the Arterial Baroreflex Function
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2018-09-01
    Completion
    2020-08-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Diabetes Mellitus, Type 2
    InterventionErtugliflozin; Hydrochlorothiazide 12.5mg; Microneurography; SKNA recordings +3 more
    PhasePhase 4
    Registry statusWithdrawn

  • ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure

    NCT03416270 · start 2018-06-28

    Registered record
    Registry ID
    NCT03416270
    Conditions
    Type 2 Diabetes Mellitus; Heart Failure
    Interventions
    Ertugliflozin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-06-28
    Completion
    2021-04-14
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus; Heart Failure
    InterventionErtugliflozin; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

    NCT02630706 · start 2015-12-16

    Registered record
    Registry ID
    NCT02630706
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Ertugliflozin 5 mg; Ertugliflozin 15 mg; Placebo matching ertugliflozin; Metformin; Glimepiride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-12-16
    Completion
    2017-12-27
    Enrolment
    506

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionErtugliflozin 5 mg; Ertugliflozin 15 mg; Placebo matching ertugliflozin; Metformin +1 more
    PhasePhase 3
    Registry statusCompleted